Bailard’s Immunomedics Inc IMMU Stock Holding History

Bailard’s Portfolio IMMU Stock Details IMMU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-53,500	Closed	-$134K	–	578
2018 Q2	$134K	Sell	53,500 -53,500	-50%	-$1.08M	0.01%	506
2018 Q1	$59K	Buy	+107,000	New	+$1.75M	﹤0.01%	473

Other funds holding IMMU

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

RP Management New York $139M AUM 37.98% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Bailard's IMMU Position: Q4 2018 in Review

Bailard sold out of Immunomedics Inc (IMMU) in Q4 2018, closing a stake of 41,000 shares — an estimated $854K sold.

Bailard first reported a position in IMMU in Q2 2013 and held it in 14 quarters. The position peaked at $4.48M in Q4 2017. 205 funds tracked by Wall St. Rank hold IMMU as of Q4 2018.

Bailard reported no remaining Immunomedics Inc position as of Q4 2018 after selling out during the quarter.
Bailard sold 41,000 Immunomedics Inc shares in Q4 2018, an estimated $854K.
Bailard first reported a position in Immunomedics Inc in Q2 2013 and held it in 14 quarters.
Bailard's Immunomedics Inc position peaked at $4.48M in Q4 2017.
205 funds tracked by Wall St. Rank held Immunomedics Inc as of Q4 2018.

Based on Bailard's 13F filing for Q4 2018, filed 5 Feb 2019.